| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Cellulose sodium phosphate (substance) |
Is a |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| lægemiddel med virkning på urogenitalapparatet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| kaliumhydrogenkarbonat 1,39 g + citronsyre 1,14 g opløselig tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| kaliumcitrat 3 g brev granulat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Sodium citrate mixture BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Sodium citrate 4 g granules for oral solution sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| ammoniumchlorid mikstur |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| natriumcitrat 3 % skyllevæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| diverse midler mod cystit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| phenazopyridinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| acidoserende middel til urinvejene |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| trimethoprim + sulfamethoxazol + phenazopyridinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 200 mg and sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Drugs for urinary retention |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| lægemidler til enuresis, pollakisuri og urininkontinens |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing hyoscyamine and phenazopyridine and secbutabarbital (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| volumenforøgende præparat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing sodium citrate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing phenazopyridine and sulfafurazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing phenazopyridine and sulfamethoxazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| azosulfamethoxazol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| natriumcitrat 4,4 g/brev pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing phenazopyridine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 95 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 150 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Phenazopyridine hydrochloride 97.2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing precisely oxytetracycline hydrochloride 250 milligram and phenazopyridine hydrochloride 50 milligram and sulfamethizole 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| oxytetracyclinhydrochlorid + phenazopyridinhydrochlorid + sulfamethizol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing ammonium chloride (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing ammonium chloride and diphenhydramine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Hydroxyapatite 830 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Hydroxyapatite 3.32 g oral granules sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Hydroxyapatite-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing ammonium chloride and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| Product containing sodium bicarbonate and sodium citrate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| carboxymethylcellulosenatrium + calciumhydroxyapatit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| carboxymethylcellulosenatrium + hydroxyapatit, injicerbart implantat, sprøjte a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
| carboxymethylcellulosenatrium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
middel til urogenital anvendelse |
Inferred relationship |
Some |
|
FHIR